[8-K] Eliem Therapeutics, Inc Common Stock Reports Material Event

Rhea-AI Filing Summary

Climb Bio, Inc. announced it furnished a press release reporting its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the company states the information is being furnished and not filed for purposes of Section 18 of the Exchange Act, meaning it is provided to investors but not incorporated into other filings by reference.

The company’s common stock trades on The Nasdaq Stock Market under the ticker CLYM. The report is signed on behalf of the registrant by Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer. Financial details themselves are contained in the attached press release.

Insights

Securities Analyst

TL;DR Routine furnishing of quarterly results; no financial figures in the filing itself, so immediate market impact is unclear.

The filing indicates Climb Bio furnished a press release with Q2 2025 results and attached it as Exhibit 99.1. Because the 8-K text does not include revenue, EPS, guidance or other metrics, the filing alone provides limited information for valuation or trading decisions. The legal note that the release is "furnished" (not "filed") clarifies it is not incorporated by reference into other filings. Investors must read Exhibit 99.1 for material financial data.

Corporate Governance Expert

TL;DR Procedurally standard disclosure; signing by the CEO is routine and the exhibit attachment follows SEC practice.

This item is a standard Item 2.02/Item 9.01 disclosure where a company furnishes a press release announcing quarterly results and attaches it as an exhibit. The registrant identified the release as furnished rather than filed, which limits legal incorporation into other filings. The presence of an executive signature confirms internal authorization; however, the 8-K does not reveal management commentary or detailed metrics within the body of the filing itself.

false000176844600017684462025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Climb Bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40708	83-2273741
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
20 William Street Suite 145
Wellesley Hills, Massachusetts				02481
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (866) 857-2596

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CLYM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Climb Bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press release of Climb Bio, Inc., dated August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Climb Bio, Inc.
Date:	August 12, 2025	By:	/s/ Aoife Brennan
			Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer

FAQ

What did Climb Bio (CLYM) disclose in this 8-K?

The company furnished a press release announcing its financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Does the 8-K include the company’s revenue or earnings figures?

No. The 8-K states the press release contains the financial results; the filing body does not include revenue, EPS, or other numeric financial details.

Is the press release considered "filed" with the SEC?

No. The company explicitly states the information, including Exhibit 99.1, is being furnished and shall not be deemed filed under Section 18 of the Exchange Act.

Where does Climb Bio trade and what is its ticker?

Climb Bio’s common stock trades on The Nasdaq Stock Market under the ticker CLYM.

Who signed the report for Climb Bio?

The report is signed on behalf of the registrant by Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer.